Literature DB >> 18196458

Current status of signal transduction modulators in the treatment of gynecologic malignancies.

Shay Ashouri1, Agustin A Garcia.   

Abstract

The introduction of platinum and paclitaxel had a pronounced effect in the prognosis and management of gynecological tumors. Preliminary results suggest that the use of signal transduction modulators, particularly inhibitors of angiogenesis has significant activity in recurrent ovarian cancer. Monoclonal antibodies against VEGF, such as bevacizumab, can be considered in the treatment of recurrent disease. Currently the role of bevacizumab as frontline therapy, in combination with cytotoxic chemotherapy, is being investigated in randomized phase III studies. It is expected that other signal transduction modulators will also have substantial activity in gynecological tumors.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18196458     DOI： 10.1007/s11864-007-0051-z

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  64 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

Review 2.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

3.  Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Authors:  Michael S Gordon; Daniela Matei; Carol Aghajanian; Ursula A Matulonis; Molly Brewer; Gini F Fleming; John D Hainsworth; Agustin A Garcia; Mark D Pegram; Russell J Schilder; David E Cohn; Lynda Roman; Mika K Derynck; Kimmie Ng; Benjamin Lyons; David E Allison; David A Eberhard; Thinh Q Pham; Randall C Dere; Beth Y Karlan
Journal:  J Clin Oncol       Date:  2006-08-08       Impact factor: 44.544

Review 4.  Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.

Authors:  L N Klapper; M H Kirschbaum; M Sela; Y Yarden
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

5.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

6.  Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.

Authors:  Dorina Belotti; Paola Paganoni; Luigi Manenti; Angela Garofalo; Sergio Marchini; Giulia Taraboletti; Raffaella Giavazzi
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

7.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

8.  Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma.

Authors:  M R Raspollini; G Amunni; A Villanucci; G Baroni; V Boddi; G L Taddei
Journal:  Int J Gynecol Cancer       Date:  2004 Sep-Oct       Impact factor: 3.437

9.  Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.

Authors:  Rakesh Kumar; Victoria B Knick; Sharon K Rudolph; Jennifer H Johnson; Renae M Crosby; Ming-Chih Crouthamel; Teresa M Hopper; Charles G Miller; Laura E Harrington; James A Onori; Robert J Mullin; Tona M Gilmer; Anne T Truesdale; Andrea H Epperly; Amogh Boloor; Jeffrey A Stafford; Deirdre K Luttrell; Mui Cheung
Journal:  Mol Cancer Ther       Date:  2007-07       Impact factor: 6.261

10.  Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.

Authors:  A Berchuck; G C Rodriguez; A Kamel; R K Dodge; J T Soper; D L Clarke-Pearson; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1991-02       Impact factor: 8.661
View more
  1 in total

1.  F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies.

Authors:  Jing Li; Yang Meng; Yue Liu; Zhi-Qiang Feng; Xiao-Guang Chen
Journal:  Invest New Drugs       Date:  2009-02-12       Impact factor: 3.850
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.